Aug 13, 2026 04:15PM
Aug 6, 2026 12:31PM
Aug 6, 2026 08:01AM
Aug 6, 2026 08:00AM
Jul 14, 2026 08:01AM
Jul 14, 2026 08:00AM
Jun 26, 2026 08:02AM Ensysce Biosciences begins final phase of opioid overdose study
Jun 26, 2026 08:00AM
May 15, 2026 04:15PM
May 12, 2026 08:09AM
May 12, 2026 08:00AM
Apr 16, 2026 08:04AM
Apr 16, 2026 08:00AM
Mar 30, 2026 04:50PM Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 3, 2026 08:02AM
Mar 3, 2026 08:00AM
Jan 5, 2026 08:03AM
Jan 5, 2026 08:00AM
Dec 2, 2025 08:05AM
Dec 2, 2025 08:00AM
Nov 20, 2025 08:00AM Ensysce Biosciences receives FDA approval for PF614 manufacturing approach
Nov 20, 2025 08:00AM
Nov 14, 2025 04:15PM
Aug 13, 2025 04:15PM
Jul 31, 2025 08:00AM
Jul 31, 2025 08:00AM
Jul 16, 2025 08:00AM
Jul 16, 2025 08:00AM Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Jun 24, 2025 08:00AM
Jun 4, 2025 08:12AM
Jun 4, 2025 08:00AM
May 13, 2025 04:15PM
Apr 15, 2025 08:04AM
Apr 15, 2025 08:00AM
Mar 10, 2025 04:15PM Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Mar 3, 2025 09:43AM
Feb 5, 2025 08:05AM
Feb 5, 2025 08:00AM
Jan 22, 2025 08:01AM
Jan 22, 2025 08:00AM
Jan 8, 2025 08:03AM
Jan 8, 2025 08:00AM Ensysce Biosciences Issues Annual Shareholder Letter
Nov 26, 2024 08:00AM
Nov 12, 2024 04:15PM
Oct 2, 2024 08:08AM
Oct 2, 2024 08:00AM
Sep 24, 2024 08:00AM
Sep 19, 2024 07:03AM
Sep 19, 2024 07:00AM Ensysce Biosciences Submits Phase 3 Protocol to the FDA
Sep 13, 2024 08:00AM

328,604 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All